Treatment of Clostridium difficile infection in pediatric patients

Susanna Esposito, Giulia Umbrello, Luca Castellazzi, Nicola Principi

Research output: Contribution to journalArticle

Abstract

Clostridium difficile causes infections that can either remain asymptomatic or manifest as clinical disease. In this report, problems, possible solutions, and future perspectives on the treatment of C. difficile infections (CDIs) in pediatric patients are discussed. CDI, despite increasing as a consequence of the overuse and misuse of antibiotics, remains relatively uncommon in pediatrics mainly because younger children are poorly susceptible to the action of C. difficile toxins. In most such cases, C. difficile disease is mild to moderate and discontinuation of the administered antibiotics in patients receiving these drugs when CDI develops, or administration of metronidazole, is sufficient to solve this problem. In severe or frequently relapsing cases, vancomycin is the drug of choice. Probiotics do not seem to add significant advantages. Other treatment options must be reserved for severe cases and be considered as a salvage treatment, although potential advantages in pediatric patients remain unclear.

Original languageEnglish
Pages (from-to)747-755
Number of pages9
JournalExpert Review of Gastroenterology and Hepatology
Volume9
Issue number6
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Clostridium Infections
Clostridium difficile
Pediatrics
Therapeutics
Anti-Bacterial Agents
Salvage Therapy
Metronidazole
Probiotics
Vancomycin
Pharmaceutical Preparations
Infection

Keywords

  • Antibiotic therapy
  • children
  • Clostridium difficile
  • fecal microbiological transplantation
  • gastrointestinal infection
  • Probiotics

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Treatment of Clostridium difficile infection in pediatric patients. / Esposito, Susanna; Umbrello, Giulia; Castellazzi, Luca; Principi, Nicola.

In: Expert Review of Gastroenterology and Hepatology, Vol. 9, No. 6, 01.07.2015, p. 747-755.

Research output: Contribution to journalArticle

Esposito, Susanna ; Umbrello, Giulia ; Castellazzi, Luca ; Principi, Nicola. / Treatment of Clostridium difficile infection in pediatric patients. In: Expert Review of Gastroenterology and Hepatology. 2015 ; Vol. 9, No. 6. pp. 747-755.
@article{bb9aeeecef46451b9cbc7523359f3248,
title = "Treatment of Clostridium difficile infection in pediatric patients",
abstract = "Clostridium difficile causes infections that can either remain asymptomatic or manifest as clinical disease. In this report, problems, possible solutions, and future perspectives on the treatment of C. difficile infections (CDIs) in pediatric patients are discussed. CDI, despite increasing as a consequence of the overuse and misuse of antibiotics, remains relatively uncommon in pediatrics mainly because younger children are poorly susceptible to the action of C. difficile toxins. In most such cases, C. difficile disease is mild to moderate and discontinuation of the administered antibiotics in patients receiving these drugs when CDI develops, or administration of metronidazole, is sufficient to solve this problem. In severe or frequently relapsing cases, vancomycin is the drug of choice. Probiotics do not seem to add significant advantages. Other treatment options must be reserved for severe cases and be considered as a salvage treatment, although potential advantages in pediatric patients remain unclear.",
keywords = "Antibiotic therapy, children, Clostridium difficile, fecal microbiological transplantation, gastrointestinal infection, Probiotics",
author = "Susanna Esposito and Giulia Umbrello and Luca Castellazzi and Nicola Principi",
year = "2015",
month = "7",
day = "1",
doi = "10.1586/17474124.2015.1039988",
language = "English",
volume = "9",
pages = "747--755",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Treatment of Clostridium difficile infection in pediatric patients

AU - Esposito, Susanna

AU - Umbrello, Giulia

AU - Castellazzi, Luca

AU - Principi, Nicola

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Clostridium difficile causes infections that can either remain asymptomatic or manifest as clinical disease. In this report, problems, possible solutions, and future perspectives on the treatment of C. difficile infections (CDIs) in pediatric patients are discussed. CDI, despite increasing as a consequence of the overuse and misuse of antibiotics, remains relatively uncommon in pediatrics mainly because younger children are poorly susceptible to the action of C. difficile toxins. In most such cases, C. difficile disease is mild to moderate and discontinuation of the administered antibiotics in patients receiving these drugs when CDI develops, or administration of metronidazole, is sufficient to solve this problem. In severe or frequently relapsing cases, vancomycin is the drug of choice. Probiotics do not seem to add significant advantages. Other treatment options must be reserved for severe cases and be considered as a salvage treatment, although potential advantages in pediatric patients remain unclear.

AB - Clostridium difficile causes infections that can either remain asymptomatic or manifest as clinical disease. In this report, problems, possible solutions, and future perspectives on the treatment of C. difficile infections (CDIs) in pediatric patients are discussed. CDI, despite increasing as a consequence of the overuse and misuse of antibiotics, remains relatively uncommon in pediatrics mainly because younger children are poorly susceptible to the action of C. difficile toxins. In most such cases, C. difficile disease is mild to moderate and discontinuation of the administered antibiotics in patients receiving these drugs when CDI develops, or administration of metronidazole, is sufficient to solve this problem. In severe or frequently relapsing cases, vancomycin is the drug of choice. Probiotics do not seem to add significant advantages. Other treatment options must be reserved for severe cases and be considered as a salvage treatment, although potential advantages in pediatric patients remain unclear.

KW - Antibiotic therapy

KW - children

KW - Clostridium difficile

KW - fecal microbiological transplantation

KW - gastrointestinal infection

KW - Probiotics

UR - http://www.scopus.com/inward/record.url?scp=84929871851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929871851&partnerID=8YFLogxK

U2 - 10.1586/17474124.2015.1039988

DO - 10.1586/17474124.2015.1039988

M3 - Article

C2 - 25912469

AN - SCOPUS:84929871851

VL - 9

SP - 747

EP - 755

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 6

ER -